{"id":"hydromorphone-hcl-oros","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL1237055","moleculeType":"Small molecule","molecularWeight":"321.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydromorphone is a semi-synthetic opioid that activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and producing analgesia. The OROS (osmotic release oral system) formulation uses osmotic pressure to deliver the drug at a controlled rate over 24 hours, providing consistent pain management with reduced dosing frequency compared to immediate-release formulations.","oneSentence":"Hydromorphone HCl OROS is an opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and is formulated as an extended-release osmotic system for sustained pain relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:40:29.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain requiring around-the-clock opioid therapy"}]},"trialDetails":[{"nctId":"NCT00631319","phase":"PHASE3","title":"A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2008-02","conditions":"Chronic Pain","enrollment":343},{"nctId":"NCT00549042","phase":"PHASE3","title":"Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2007-10","conditions":"Chronic Low Back Pain","enrollment":459},{"nctId":"NCT00410878","phase":"PHASE1","title":"A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":22},{"nctId":"NCT01824524","phase":"PHASE1","title":"A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2011-12","conditions":"Pain","enrollment":12},{"nctId":"NCT00261495","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2006-03","conditions":"Pain","enrollment":504},{"nctId":"NCT00980798","phase":"PHASE3","title":"Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2007-10","conditions":"Pain, Osteoarthritis, Hip, Osteoarthritis, Knee","enrollment":288},{"nctId":"NCT01532895","phase":"","title":"Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2011-09","conditions":"Pain","enrollment":400},{"nctId":"NCT01205126","phase":"PHASE3","title":"An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-12","conditions":"Pain","enrollment":260},{"nctId":"NCT00766831","phase":"PHASE4","title":"An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-10","conditions":"Cancer Pain","enrollment":190},{"nctId":"NCT01648699","phase":"PHASE4","title":"Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain","status":"TERMINATED","sponsor":"Janssen Pharmaceutica","startDate":"2010-04","conditions":"Pain","enrollment":20},{"nctId":"NCT01621100","phase":"PHASE4","title":"Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2011-12","conditions":"Cancer Pain","enrollment":106},{"nctId":"NCT01273454","phase":"","title":"An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2009-06","conditions":"Pain","enrollment":648},{"nctId":"NCT00803283","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain","status":"TERMINATED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-11","conditions":"Cancer Pain","enrollment":2},{"nctId":"NCT01006356","phase":"PHASE4","title":"An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-10","conditions":"Cancer, Pain","enrollment":141},{"nctId":"NCT00411164","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"2003-11","conditions":"Osteoarthritis, Hip, Osteoarthritis, Knee","enrollment":990},{"nctId":"NCT01487564","phase":"PHASE1","title":"Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT01487512","phase":"PHASE1","title":"Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-03","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT00411034","phase":"PHASE3","title":"A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesics, Opioid, Pain","enrollment":463},{"nctId":"NCT00399295","phase":"PHASE1","title":"An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesia","enrollment":30},{"nctId":"NCT00398957","phase":"PHASE1","title":"An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesia","enrollment":32},{"nctId":"NCT00410787","phase":"PHASE3","title":"Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesics, Opioid, Pain","enrollment":68},{"nctId":"NCT00410540","phase":"PHASE3","title":"A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":202},{"nctId":"NCT00399048","phase":"PHASE3","title":"An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":140},{"nctId":"NCT00398788","phase":"PHASE2","title":"A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Low Back Pain","enrollment":207},{"nctId":"NCT00410748","phase":"PHASE3","title":"Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":388},{"nctId":"NCT00411268","phase":"PHASE3","title":"Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Low Back Pain","enrollment":207},{"nctId":"NCT00410644","phase":"PHASE3","title":"A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":463},{"nctId":"NCT00410943","phase":"PHASE3","title":"Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain","enrollment":169},{"nctId":"NCT00411307","phase":"PHASE2","title":"A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Postoperative, Orthopedic Procedures, Analgesia","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hydromorphone HCl OROS","genericName":"Hydromorphone HCl OROS","companyName":"Janssen Korea, Ltd., Korea","companyId":"janssen-korea-ltd-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydromorphone HCl OROS is an opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and is formulated as an extended-release osmotic system for sustained pain relief. Used for Moderate to severe chronic pain requiring around-the-clock opioid therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}